Bevacizumab

Outlook Therapeutics, Inc. (OTLK) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Outlook Therapeutics, Inc.

Retrieved on: 
Thursday, November 9, 2023
Class Action Lawsuit, Professional Services, Legal, Safety, Efficacy, Therapy, BLA, LLP, Bevacizumab, Complaint, Viability, Agency, FDA, Person, AMD, CMC, News, Inc.

Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Outlook Therapeutics, Inc. (NASDAQ: OTLK) securities between December 29, 2022 and August 29, 2023.

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Outlook Therapeutics, Inc. (NASDAQ: OTLK) securities between December 29, 2022 and August 29, 2023.
  • Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Outlook Therapeutics, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

VEGZELMA® (bevacizumab-adcd) receives preferred formulary status with Ventegra® for commercially insured patients

Retrieved on: 
Monday, December 11, 2023
Urine, Reproduction, Skeleton, Headache, PSA, Kidney, Erythroderma, Patient, Pharmacy, Birth, Nephrotic syndrome, MBA, Cancer, Miscarriage, Safety, Incidence, VTE, Bevacizumab, Corneal opacity, Wound healing, VEGFR2, Gastrointestinal perforation, Hemoptysis, Female, Fetus, CHF, Celltrion, Pharming, Necrotizing fasciitis, Heart failure, Fistula, Risk, Tracheoesophageal fistula, Bleeding, Organogenesis, Partnership, Rhinitis, Hypertension, Primary ovarian insufficiency, Back pain, Pregnancy, Glioblastoma, PRES, Nosebleed, Skull, FDA, ATE, VEGF, MBM, Hypertensive encephalopathy, Toxicity, Nursing, Pharmaceutical industry, Birth control, Dietary supplement, Proteinuria

Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.

Key Points: 
  • Ventegra's proprietary formulary program (which includes Formulary Shield and the Ventegra Specialty Inclusion Program) is available for access by more than 400 clients and 13 million members/patients that are enrolled with Ventegra.
  • Gastrointestinal Perforations and Fistula: Discontinue for gastrointestinal perforations, tracheoesophageal fistula, grade 4 fistula, or fistula formation involving any organ.
  • Surgery and Wound Healing Complications: In patients who experience wound healing complications during VEGZELMA treatment, withhold VEGZELMA until adequate wound healing.
  • Do not administer VEGZELMA for at least 28 days following a major surgery, and until adequate wound healing.

MEDSIR presents promising results at SABCS 2023: ATRACTIB and DEBBRAH trials hold potential to improve the lives of advanced breast cancer patients

Retrieved on: 
Friday, December 8, 2023
Paclitaxel, Peripheral neuropathy, PD-L1, Brain, Research, Safety, SAN, Toxicity, Progression-free survival, Cohort, Bevacizumab, Hospital, Breast cancer, Fatigue, Patient, Triple-negative breast cancer, Trastuzumab deruxtecan, Neutropenia, HER2, Survival, Death, Cancer, Immunotherapy, Knowledge, HIV disease progression rates, TNBC, Medical imaging, Pharmaceutical industry

The results from the ATRACTIB trial, focusing on advanced triple-negative breast cancer (TNBC), and DEBBRAH Cohort 5, centered on HER2[+] or HER2-Low advanced breast cancer with leptomeningeal carcinomatosis, offer new hope for patients with limited treatment alternatives.

Key Points: 
  • The results from the ATRACTIB trial, focusing on advanced triple-negative breast cancer (TNBC), and DEBBRAH Cohort 5, centered on HER2[+] or HER2-Low advanced breast cancer with leptomeningeal carcinomatosis, offer new hope for patients with limited treatment alternatives.
  • This phase II clinical trial highlights the success of a combined therapy approach as a first-line treatment for advanced TNBC patients.
  • The DEBBRAH trial, focusing on HER2[+] or HER2-Low advanced breast cancer patients with brain metastases and/or leptomeningeal carcinomatosis, showcased promising results from Cohort 5, which specifically included patients with pathologically confirmed leptomeningeal carcinomatosis.
  • This rare but serious complication occurs in approximately 10% of advanced breast cancer patients and is associated with poor outcomes and limited therapeutic options.

FDA Approves Bio-Thera Solutions' Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®

Retrieved on: 
Thursday, December 7, 2023
USFDA, Lung, Safety, Patient, FDA, Lung cancer, Pharmacokinetics, Novartis, Biosimilar, Generic drug, Bevacizumab

Avzivi® is Bio-Thera's second USFDA approved product and is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.

Key Points: 
  • Avzivi® is Bio-Thera's second USFDA approved product and is the second biosimilar researched, developed, and manufactured by a Chinese pharmaceutical company to receive FDA approval in the United States.
  • The FDA approval of Avzivi® was based on a comprehensive analytical, non-clinical and clinical data package submitted by Bio-Thera to the FDA.
  • Extensive analytical characterization between BAT1706 and US and EU Avastin® was conducted on structural, physicochemical, and biological properties to support biosimilarity of BAT1706.
  • The approval of Avzivi® by the FDA will provide lung and colorectal cancer patients a new cost-effective treatment option.

Shattuck Labs Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, November 9, 2023
Bevacizumab, Patient, Neoplasm, Headache, Acute myeloid leukemia, Optimism, Mirvetuximab soravtansine, Clinical trial, PROC, Fatigue, Embolism, IRR, TP53, Thrombocytopenia, Macrophage, Conference, PLD, Nausea, Society, ASH, Pharmacokinetics, Pfizer, Autoimmune disease, AZA, Platinum, Anemia, Safety, Cancer, Conference call, Neutropenia, AML, Pharmaceutical industry, Azacitidine

AUSTIN, TX and DURHAM, NC, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.

Key Points: 
  • ET –
    AUSTIN, TX and DURHAM, NC, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.
  • Shattuck remains on track to share initial data in the fourth quarter of 2023 from the frontline expansion cohorts in TP53 mutant AML and HR-MDS.
  • ET today to review third quarter 2023 financial results and provide a general business overview.
  • General and Administrative (G&A) Expenses: G&A expenses were $5.1 million for the quarter ended September 30, 2023, as compared to $6.6 million for the quarter ended September 30, 2022.

OTLK INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Outlook Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Retrieved on: 
Thursday, November 9, 2023
Bevacizumab, FDA, Food, Agency, AMD, CMC, CASE, News, Regulation of tobacco by the U.S. Food and Drug Administration, Outlook, Safety, Therapy, BLA, SAN, Medical device, Tobacco, Pharmaceutical industry

), the Outlook Therapeutics class action lawsuit charges Outlook Therapeutics and certain of its top executive officers with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Outlook Therapeutics class action lawsuit charges Outlook Therapeutics and certain of its top executive officers with violations of the Securities Exchange Act of 1934.
  • A lead plaintiff acts on behalf of all other class members in directing the Outlook Therapeutics class action lawsuit.
  • The lead plaintiff can select a law firm of its choice to litigate the Outlook Therapeutics class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Outlook Therapeutics class action lawsuit.

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
Bevacizumab, Research, PD-L1, Standard of care, Kidney cancer, ATM, Therapy, Pembrolizumab, PFS, TREX1, Liver cancer, Partnership, Lead, Patient, OS, Mutation, Pharmaceutical industry, Medical imaging, Cryptocurrency, Gunsmith, Birth control, Rare-earth element, Tempest

BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • BRISBANE, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  • The results for the quarter-to-date period are preliminary, unaudited and are not necessarily indicative of the results that may be expected for the full quarter or year ending December 31, 2023.
  • Research and development expenses for the quarter ended September 30, 2023 were $4.2 million compared to $6.0 million for the same period in 2022.
  • General and administrative expenses for the quarter ended September 30, 2023 were $2.4 million compared to $2.8 million for the same period in 2022.

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Outlook Therapeutics, Inc. (BCS)

Retrieved on: 
Tuesday, November 7, 2023
Bevacizumab, FDA, Complaint, Agency, Viability, AMD, CMC, Person, News, LLP, Efficacy, Safety, Therapy, BLA, SAN, Pharmaceutical industry, Inc.

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Outlook Therapeutics, Inc. (NASDAQ: OTLK) securities between December 29, 2022 and August 29, 2023.

Key Points: 
  • SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Outlook Therapeutics, Inc. (NASDAQ: OTLK) securities between December 29, 2022 and August 29, 2023.
  • Outlook is a late clinical-stage biopharmaceutical company that focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Outlook Therapeutics, Inc. Shareholders who want to act as lead plaintiff for the class should contact Robbins LLP.

OUTLOOK THERAPEUTICS, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Outlook Therapeutics, Inc. (NASDAQ: OTLK)

Retrieved on: 
Tuesday, November 7, 2023
Bevacizumab, FDA, AMD, CMC, News, Court, Complaint, District court, Safety, Advertising, Therapy, Action Replay, BLA, Defendant, Pharmaceutical industry, Security (finance), Outlook

Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Outlook Therapeutics, Inc. (“Outlook” or the “Company”) (NASDAQ: OTLK) between December 29, 2022 and August 29, 2023, inclusive (the “Class Period”).
  • If you purchased or acquired Outlook securities, and/or would like to discuss your legal rights and options please visit Outlook Therapeutics, Inc.
  • If you purchased or acquired Outlook securities, and/or would like to discuss your legal rights and options please visit Outlook Therapeutics, Inc.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Bevacizumab, Patient, FDA, Research, Carboplatin, RP1, NMSC, Biologics license application, Nivolumab, Biotechnology, Financial management, Carcinoma, Cisplatin, Data collection, Disclosure, SITC, Immunotherapy, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Initiation, RP3, Clinical trial, Marketing, Melanoma, Skin, Annual general meeting, RP2, PTC, CFO, Roche, Society, CSCC, PTC Therapeutics, Therapy, Investment, Calendar, BLA, D, Merkel-cell carcinoma, Pharmaceutical industry, Nursing, Cryptocurrency

WOBURN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced financial results for the fiscal second quarter ended September 30, 2023 and provided a business update.

Key Points: 
  • R&D Expenses: Research and development expenses were $49.1 million for the second quarter ended September 30, 2023, as compared to $28.8 million for the second quarter ended September 30, 2022.
  • S,G&A Expenses: Selling, general and administrative expenses were $14.7 million for the second quarter ended September 30, 2023, as compared to $12.7 million for the second quarter ended September 30, 2022.
  • Selling, general and administrative expenses included $4.7 million in stock-based compensation expenses for the second quarter ended September 30, 2023.
  • Net Loss: Net loss was $60.0 million for the second quarter ended September 30, 2023, as compared to a net loss of $43.1 million for the second quarter ended September 30, 2022.